GC-101 is under clinical development by Shanghai Gencells Therapeutics and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GC-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GC-101 is under development for the treatment of gastrointestinal tumors, epidermolysis bullosa, advanced solid tumors, metastasized breast cancer, glioma, advanced melanoma, hepatobiliary cancer, cervical cancer, head and neck squamous cell tumors, non-small cell lung cancer, breast cancer and pancreatic cancer. It is administered through parenteral and intravenous route. The therapy comprises of autologous tumor infiltrating lymphocytes (TILs).
Shanghai Gencells Therapeutics overview
Shanghai Gencells Therapeutics is a clinical-stage cell therapy platform company. It is headquartered in Shanghai, China.
For a complete picture of GC-101’s drug-specific PTSR and LoA scores, buy the report here.